Posts

CBD oil kills gonorrhoea bacteria, potential for ‘much-needed new class of antibiotics’

Groundbreaking new research has found synthetic cannabidiol can kill bacteria associated with gonorrhoea, meningitis and legionnaires disease.

The research, published in a peer-reviewed journal article in Communications Biology on Wednesday, explores antimicrobial activity of CBD and the potential to advance CBD analogs as a “much-needed new class of antibiotics”.

It found the psychoactive component of cannabis could kill a subset of gram-negative bacteria including neisseria gonorrhoeal, which causes gonorrhoea, Australia’s second most common sexually-transmitted disease.

Click through to read the full article on The Australian here.

Qld researchers on how cannabis could be used to fight superbug

Queensland researchers are studying a component of medicinal cannabis for its potential as a new antibiotic, capable of killing superbugs.

The big hope for scientists at the University of Queensland’s Institute for Molecular Bioscience is that synthetic cannabidiol, or CBD, the main non-psychoactive component of cannabis, could be developed into the first new class of antibiotics for drug-resistant bacteria in more than half a century.

The quest for new antibiotics is seen as crucial by infectious disease experts, with predictions that by 2050, drug-resistant infections could result in 10 million deaths a year unless alternate treatments are found.

Click through to read the full article on The Courier Mail here.

UQ media release | Research establishes antibiotic potential for cannabis molecule

Synthetic cannabidiol, better known as CBD, has been shown for the first time to kill the bacteria responsible for gonorrhoea, meningitis and legionnaires disease.

The research collaboration between The University of Queensland and Botanix Pharmaceuticals Limited could lead to the first new class of antibiotics for resistant bacteria in 60 years.

The UQ Institute for Molecular Bioscience’s Associate Professor Mark Blaskovich said CBD – the main nonpsychoactive component of cannabis – can penetrate and kill a wide range of bacteria including Neisseria gonorrhoeae, which causes gonorrhoea.

“This is the first time CBD has been shown to kill some types of Gram-negative bacteria. These bacteria have an extra outer membrane, an additional line of defence that makes it harder for antibiotics to penetrate,” Dr Blaskovich said.

In Australia, gonorrhoea is the second most common sexually-transmitted infection and there is no longer a single reliable antibiotic to treat it because the bacteria is particularly good at developing resistance.

The study also showed that CBD was widely effective against a much larger number of Gram-positive bacteria than previously known, including antibiotic-resistant pathogens such as MRSA (methicillin-resistant Staphylococcus aureus) or ‘golden staph’.

Dr Blaskovich said cannabidiol was particularly good at breaking down biofilms—the slimy build-up of bacteria, such as dental plaque on the surface of teeth—which help bacteria such as MRSA survive antibiotic treatments.

Dr Blaskovich’s team at the Centre for Superbug Solutions mimicked a two-week patient treatment in laboratory models to see how fast the bacteria mutated to try to outwit CBD’s killing power.

“Cannabidiol showed a low tendency to cause resistance in bacteria even when we sped up potential development by increasing concentrations of the antibiotic during ‘treatment’.”

“We think that cannabidiol kills bacteria by bursting their outer cell membranes, but we don’t know yet exactly how it does that, and need to do further research.

The research team also discovered that chemical analogs – created by slightly changing CBD’s molecular structure—were also active against the bacteria.

“This is particularly exciting because there have been no new molecular classes of antibiotics for Gram-negative infections discovered and approved since the 1960s, and we can now consider designing new analogs of CBD within improved properties.”

Vince Ippolito, the President and Executive Chairman of Botanix, said the research showed vast potential for the development of effective treatments to fight the growing global threat of antibiotic resistance.

“Congratulations to Dr Blaskovich and his team for producing this significant body of research—the published data clearly establishes the potential of synthetic cannabinoids as antimicrobials,” Mr Ippolito said.

“Our Company is now primed to commercialise viable antimicrobial treatments which we hope will reach more patients in the near future. This is a major breakthrough that the world needs now.”

Dr Blaskovich said collaborating with Botanix has sped up the research, with Botanix contributing formulation expertise that has led to the discovery that how cannabidiol is delivered makes a huge difference in its effectiveness at killing bacteria.

The collaboration has enabled Botanix to progress a topical CBD formulation into clinical trials for decolonisation of MRSA before surgery.

“Those Phase 2a clinical results are expected early this year and we hope that this will pave the way forward for treatments for gonorrhoea, meningitis and legionnaires disease.

“Now we have established that cannabidiol is effective against these Gram-negative bacteria, we are looking at its mode of action, improving its activity and finding other similar molecules to open up the way for a new class of antibiotics.”

JOURNAL ARTICLE:

This research has been published in Communications Biology. See journal article HERE.

VIDEO:

Video news release and b-roll package is available HERE.

MEDIA:

H^CK Director, haley@hck.digital, +61 423 139 163 | Dr Mark Blaskovich, m.blaskovich@imb.uq.edu.au, +61 (0) 414 955380 | IMB Communications, communications@imb.uq.edu.au, +61 (0) 405 661856;

– ENDS –

Botanix Pharmaceuticals updates on meeting with FDA

AusBiotech’s BiotechDispatch featured our BTX 1801 antimicrobial program update today.

Read the full article here.

Botanix Pharmaceuticals (ASX:BOT) gets U.S. FDA clearance for BTX 1801 development

Botanix Pharmaceuticals (BOT) has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration’s (FDA) Office of Infectious Diseases.

The meeting assessed the potential of initiating clinical development of the company’s BTX 1801 antimicrobial drug for preventing surgical site infections (SSIs) in the U.S.

It also enabled the company to receive feedback from the FDA on the drug development plan needed for BTX 1801 to support a Fast Track designation and New Drug Application (NDA).

Click through to read the full article on The Market Herald here.

Botanix Pharma Talks With FDA on Antibacterial Drug

The Green Fund has published a summary of Botanix Pharmaceutical’s BTX 1801 announcement today, an update on the development pathway for our BTX 1801 antimicrobial product.

Take a look at the article here.

BTX 1801 Update

Botanix (ASX:BOT) has today announced it has secured a clear development path from the FDA for its BTX 1801 synthetic cannabidiol antimicrobial product, following the successful completion of a Pre-Investigational New Drug (Pre-IND) meeting.

Our team will have more clinical data to share soon too – our BTX 1801 Phase 2a study in Perth is fully enrolled and remains on track for completion before the end of this calendar year.

Read today’s ASX release here.

Quarterly Report

Botanix Pharmaceuticals has released its latest Quarterly Report – a period which has delivered a series of progress milestones.

In our antimicrobial program, we commenced a Phase 2a clinical trial for BTX 1801 to study the use of synthetic cannabidiol in the prevention of surgical site infections. We also shared new data from an ex vivo efficacy study, which further validates the mechanism of action of our antimicrobial platform.

In our dermatology program, we successfully completed an End of phase 2 meeting with the FDA for our BTX 1503 acne product. We’re also looking forward to commencing recruitment for our BTX 1702 program for the treatment of Rosacea, when COVID-19 travel restrictions ease.

Read the full report here.

Antimicrobial resistance: a global health emergency

Botanix has appeared in a must-read feature about antimicrobial resistance (AMR) in the latest edition of AusBiotech’s Australasian Biotechnology Journal.

It is titled, “Antimicrobial resistance: a global health emergency”.

A quote from WHO Director-General Dr Tedros Adhanom Ghebreyesus, featured in the story, points to the importance of the work we are doing in this space:

“AMR is a slow tsunami that threatens to undo a century of medical progress. A record number of countries are now monitoring and reporting on antibiotic resistance to WHO”.

Read the full story on pages 52-54 here.

Why I think these small cap ASX shares will perform in 2021

The Motley Fool’s Aaron Teboneras featured Botanix Pharmaceuticals as a top stock pick in an article today.

“At the time of writing, the Botanix share price is trading at 10 cents, up 7.5% for the day. With a market capitalisation of $97 million, if the company can perform to market expectations, its share price will soar.”

Read the full article here.